Abstract
Mineralocorticoid receptor antagonists (MRAs) that block aldosterone's effects on both epithelial and non-epithelial receptors have become a mainstay of therapy for chronic heart failure. Given that cardiovascular events remain the leading cause of death for patients with end-stage renal disease (ESRD), the question of whether these MRAs can be employed in dialysis patients arises. This review summarizes the rationale for blocking aldosterone in patients with chronic and end-stage kidney disease and surveys the data on both the efficacy and safety of using MRAs in the ESRD population. A small but growing body of literature suggests that use of MRAs by ESRD patients is associated with lower blood pressure, reduced left ventricular (LV) mass, and improved LV ejection fraction. Recently, a large randomized trial found an overall 3-year mortality rate of 6.4% in ESRD patients on spironolactone 25 mg daily vs. 19.7% in ESRD patients on no MRA therapy (p = 0.002), without a significantly increased risk of hyperkalemia.
Citations
Jan 13, 2018·Clinical Science·Alison H M TaylorPatrick B Mark
Dec 1, 2018·Journal of Hypertension·Giuseppe Maiolino, Lorenzo A Calò
Feb 8, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Simon D RogerDavid K Packham
Oct 19, 2016·Current Opinion in Nephrology and Hypertension·Omar Al Dhaybi, George Bakris
Nov 5, 2016·The Journal of Clinical Hypertension·Heiko M MundtUrs Benck
Jul 18, 2020·Clinical Journal of the American Society of Nephrology : CJASN·Ahmed M ShamanMin Jun
Apr 30, 2017·Current Hypertension Reports·Radmila Lyubarova, Elvira O Gosmanova
Apr 17, 2019·Journal of Nephrology·Irene CapelliGaetano La Manna
Aug 28, 2020·Hemodialysis International·Daljit K Hothi, Matthew Fenton
Jul 16, 2017·International Urology and Nephrology·Rafał DonderskiJacek Manitius
Jan 20, 2019·Current Hypertension Reports·Michelle A FravelMony Fraer
May 20, 2016·International Urology and Nephrology·RenJie LuFenglei Tang
Oct 1, 2019·American Journal of Therapeutics·Timothy NguyenJessica J Balaoro
Jun 19, 2021·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Daljit K Hothi